In both monocrotaline and Sugen–Hypoxia-treated rat pulmonary arterial hypertension models, a 2-week treatment with the poly (ADP-ribose) polymerase 1 inhibitor ABT-888 after the establishment of the disease was able to reverse the pulmonary arterial hypertension phenotype40. This evidence concerns the gene PARP1 and pulmonary arterial hypertension.